Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study.

Cancers (Basel) · 2021 · PMC8036307 · PMID 33915693

Europe PMC DOI

hedged sentence

0.1040

closest p · 2.1× alpha

0.1040

boldest claim

The sentences

did not reach statistical significancep = 0.104not close (p > 0.1)

CKD appeared to be a potential effect modifier for overall survival in RCC that, however, did not reach statistical significance (NR, 95%CI:15.27-NR vs. 23.9 months, 95%CI:18.19-NR; HR 0.502 (95%CI 0.219–1.152), p = 0.104) ( Figure 1 B and Table 7 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.